Clinical Trial Update: A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia [Phase 1]

View source ↗

Summary

This clinical-trial update describes a Phase 1 safety and tolerability extension study of repeated dosing with an anti-KIR monoclonal antibody (IPH2101/1-7F9) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Lirilumab (IPH2101, 1-7F9) (lirilumab)

Snippet

Sponsor: Innate Pharma | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED